▎WuXiEdited by the Kant Content Team

GSK and CureVac Announce Restructuring of Collaboration into New Licensing Agreement to Prioritize mRNA Development Activities; CureVac to Receive Approximately €1.5 Billion

Under the terms of the new agreement, GSK will take full responsibility for the development and production of these candidate vaccines. GSK will have the right to commercialize these candidate vaccines globally.This agreement represents the latest step in GSK's ongoing investment in vaccine platform technology, aiming to develop the best-matched platform for each pathogen to create potentially "best-in-class" vaccines. mRNA is a highly adaptable vaccine technology capable of addressing rapid viral strain changes and demonstrating application potential against emerging viruses.GSK continues to develop and optimize its mRNA platform capabilities through investment and collaboration, including AI/ML-based sequence optimization, and the design and production of nanoparticles.

According to the agreement,CureVac to Receive €400 Million Upfront Payment and Up to €1.05 Billion in Development and Regulatory MilestonesThe new agreement replaces all financial terms of the previous cooperation agreement between GSK and CureVac.CureVac retains the rights to undisclosed projects from prior collaborations that have been preclinically validated and target infectious diseases, and has the right to independently or collaboratively develop mRNA vaccines for any other infectious diseases or indications.

References:

[1] GSK and CureVac to restructure collaboration into new licensing agreement. Retrieved July 3, 2024 from https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their WeChat Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For reprint authorization, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.